At a glance
ClinicalIndex Comparison Record- ✓Diagnosis of indolent or aggressive B-cell NHL (follicular grades 1-3, mantle cell, small lymphocytic, diffuse large B-cell, diffuse mixed, or marginal zone)
- ✓Relapsed or refractory CD20-positive disease
- ✓Measurable disease
- ✓Prior receipt of 1-3 standard chemotherapy regimens
- ✕Burkitt lymphoma or precursor B-lymphoblastic lymphoma
- ✕CNS lymphoma
- ✕History of New York Heart Association class II-IV cardiac disease or congestive heart failure
- ✕Prior cumulative doxorubicin (or equivalent anthracycline) dose >400 mg/m²
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Pilot Study of the Safety and Efficacy of Rituxan (Chimeric Anti-CD20 Antibody) in Combination With Doxil (Liposomal Doxorubicin) Chemotherapy in Patients With Relapsing or Refractory Indolent or Aggressive B-Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating rituximab and pegylated liposomal doxorubicin hydrochloride for Lymphoma. Completed, enrolled 42 participants across 1 site.
Detailed Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as liposomal doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with liposomal doxorubicin may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects of giving rituximab together with liposomal doxorubicin and to see how well they work in treating patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Study Details
Timeline
Interventions
IV
IV